GeoVax Labs, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from GeoVax Labs, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 2,367% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 2,953% in 3 years, but profit fell: $309 less profit per $100 of extra sales. Lower than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-733.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$309Sales grew 2,953% in 3 years, but profit fell: $309 less profit per $100 of extra sales.
Lower than 92% of Healthcare companies in United States.
Asset Productivity Ratio
+2953% / -80%In 3 years sales changed by +2953% while total assets changed by -80%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-81.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 80% of Healthcare companies in United States.
Cash Cushion Ratio
1.0× cashCash, after subtracting all debt, is 1.0 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 90% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 91% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
GeoVax Labs, Inc. made a loss over the last year. GeoVax Labs, Inc. owes $0.62 for every $1 it owns. GeoVax Labs, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGeoVax Labs, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.22The share price is 1.22 times GeoVax Labs, Inc.'s book value per share, lower than 75% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of GeoVax Labs, Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat GeoVax Labs, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.17Net worth divided by the number of shares. The share price of $0.21 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-891.6%GeoVax Labs, Inc. lost 891.6% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
Owes vs Owns
0.62×GeoVax Labs, Inc. owes $0.62 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Dividend yield
NoneGeoVax Labs, Inc. does not currently pay a dividend.
Revenue growth
-37%Revenue fell 37% in the year to Dec 2025, and grew 213% a year on average over 3 years.
Profit growth
LossGeoVax Labs, Inc. made a loss in each of the last two years.
Profit margin
-862.3%GeoVax Labs, Inc. lost $862 for every $100 of revenue.
Cash vs debt
Net cashGeoVax Labs, Inc. held $2 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For GeoVax Labs, Inc.: $2 M ÷ $2 M (30 Jun 2026) = 1.2.
What is GeoVax Labs, Inc.'s return on equity?
GeoVax Labs, Inc. lost 891.6% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
How much does GeoVax Labs, Inc. owe compared with what it owns?
GeoVax Labs, Inc. owes $0.62 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Does GeoVax Labs, Inc. pay a dividend?
No. GeoVax Labs, Inc. does not currently pay a dividend.
Is GeoVax Labs, Inc.'s revenue growing?
Revenue fell 37% in the year to Dec 2025, and grew 213% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.